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ABSTRACT 
One approach to gene therapy for human cancer is transcatheter injection of DNA liposomes into tumor 
masses. T o determine the feasibility of selective delivery of recombinant genes by a catheter to the pulmonary 
vasculature in humans, a patient with melanoma received two treatments of H L A - B 7 plasmid D N A complexed 
to cationic liposomes into a right posterior basal pulmonary artery associated with a mass lesion. The 
treatments were well tolerated. N o adverse respiratory, cardiac, immunologic, or other organ toxicities were 
detected. The delivery of recombinant genes by catheter m a y be a useful modality to treat h u m a n malignancy 
and other diseases. 
OVERVIEW SUMMARY 
Transcatheter delivery of HLA-B7 DNA and cationic lipo-
somes into a segment of a pulmonary artery was safely 
perfonned in 1 patient with tumor nodules in the lung. No 
immunologic or organ toxicities were observed. Percutane-
ous catheter gene delivery has been performed in humans. 
Further refinements of this approach may lead to useful 
treatments for a variety of human diseases. 
INTRODUCTION 
ONE APPROACH TO CANCER IMMUNOTHERAPY is the direct 
transmission of recombinant genes into established tu-
mors to modulate the immune response directed against tumor 
growth (Plautz et al., 1993). Recombinant genes can be directly 
introduced into tumors by injection of subcutaneous tumor nod-
ules or by catheter delivery into the vasculature of parenchymal 
masses (Nabel et al., 1993a). Therapeutic drugs are routinely 
delivered to selective sites in the circulation by catheters to treat 
vascular diseases (Keimedy et al., 1985; Ambrose et al., 1992) 
and parenchymal tumors (Ensminger, 1993). Transcatheter in-
troduction of recombinant genes and vectors to selective re-
gions of the vasculature has been established in preclinical 
animal models (Nabel et al., 1990; LeClerc et al., 1992; Barr 
etal., 1994), but tbe toxicities and safety of catheter-based gene 
delivery in humans has not been explored. W e report here the 
delivery of a class I major histocompatibility complex (MHC) 
gene in cationic liposomes by transcatheter injection into 
the right posterior basal pulmonary artery and surrounding right 
lower lobe tumor mass in a patient enrolled in a human gene 
therapy protocol for immunotherapy of melanoma. The find-
ings suggest that transcatheter dehvery of genetic material in 
this patient appears safe and well tolerated. This approach may 
be applicable to the genetic treatment of cancer and vascular 
diseases. 
MATERIALS AND METHODS 
Informed consent was obtained according to the Committee 
to Review Grants for Clinical Research and Investigations In-
volving Human Beings of the University of Michigan Medical 
School, the Recombinant D N A Advisory Committee of the 
National Institutes of Health, and the Food and Drug Adminis-
tration. 
Departments of 'Internal Medicine, ̂ Surgery, ''Radiology, and 'Biological Chemistry, ̂ Howard Hughes Medical Institate, University of 
Michigan Medical Center, Ann Moot, MI 48109-0688. 
^Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. 
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Vector production 
A eukaryotic expression vector plasmid, pHLA-B7, was pre-
pared by insertion of an H L A - B 7 c D N A into the Rous sarcoma 
virus p-globin plasmid as previously described (Nabel et al., 
1993a). H L A - B 7 DNA-liposome complexes were prepared 
just prior to catheterization by adding 0.1 ml of lactated Ringer 
solution into a sterile vial of H L A - B 7 plasmid D N A (20 (ig/ml; 
0.1 ml). A n aliquot of this solution (0.1 ml) was added to 0.1 ml 
of 150 pJW dioleoyl phosphatidylethanolamine/3b-[Af-N',Af'-
dimethylaminoethane) carbamoyl] cholesterol liposome (Gao 
and Huang, 1991) in lactated Ringer solution in a separate 
sterile vial. The solution was allowed to incubate for 15 min at 
room temperatore, and 0.5 ml of sterile lactated Ringers was 
added to the vial and mixed. The D N A , liposomes, and sterile 
vials were prepared in accordance with Food and Drug Admin-
istration guidelines and quality control procedures, as has been 
previously described (Nabel et al., 1993a). 
Gene transfer 
Percutaneous right heart catheterization was performed from 
the right femoral vein using sterile techniques. A n 8 French 
sheath was inserted into the right femoral vein, and a 7 French 
Van A m a n pigtail catheter was advanced into the right pulmo-
nary artery under fluoroscopic guidance. After pressure mea-
surement, selective catheterization of the right posterior basal 
segment artery was performed, and the Van A m e n catheter Was 
exchanged for a 5 French occlusion balloon catheter (Medi-
Tech, Watertown, M A ) over a 0.025-inch exchange guidewire. 
After balloon inflation, digital subtraction angiography was 
performed to confirm catheter position and arrest of blood flow 
(Fig. 1). Confirmation that blood flow was arrested was deter-
mined by inflation of the balloon and injection of intravenous 
contrast dye into the vascular space. N o diffusion of the contrast 
material was noted over a 5-min period, thus ensuring that 
delivery of D N A and liposomes would proceed antegrade in the 
vasculatore and not immediately admix with blood to inactivate 
the DNA-liposome complex. The posterior basal segment ar-
tery was rinsed with 30 ml of sterile saline, and the H L A - B 7 
DNA-liposome solution, 1.43 |xg of D N A in a volume of 0.6 
ml, was instilled followed by an additional 1.0 ml of sterile 
saline. This solution was injected through the end hole of the 
catheter into the posterior basal segment artery. A n additional 
3.0 ml of sterile sahne was instilled through the catheter, and 
the HLA-B7 DNA-liposome solution incubated for 20 min to 
achieve transduction of the local microcirculation. The balloon 
was deflated, and the catheter and femoral sheath were re-
moved. 
Hemodynamic and biochemical monitoring 
To determine the effects of DNA-liposome delivery to the 
pulmonary vasculatore, hemodynamic and biochemical moni-
toring was performed. The patient's electrocardiogram (ECG) 
(six-lead) was continuously recorded prior to, during, and after 
injection of the DNA-liposome solution. Pulmonary artery, 
pulmonary capillary wedge pressure, and systemic blood 
pressure were measured 5 min prior to gene transfer and 20 
min after delivery of D N A and liposomes. Biochemical para-
FIG. 1. Digital subtraction angiography of right posterior 
basal segment artery. After selective catheterization of the right 
posterior basal artery, a digital subtraction angiogram was per-
formed. The intravenous contrast agent demonstrates displace-
ment of the posterior basal segmental arteries by the tomor. The 
contrast agent was removed by instillation of 30 ml of sterile 
saline solution followed by the introduction of 1.43 |Jig of 
pHLA-B7 plasmid D N A complexed to DC-cholesterol lipo-
meters were also measured 1 day before and 1 day after each 
treatment. 
RESULTS 
A 68-year-old male with stage IV metastatic melanoma was 
enrolled in a human gene therapy clinical protocol. "Immuno-
therapy of malignancy by in vivo gene transfer into tomors" 
(Nabel et al., 1992), based upon clinical guidelines. This pa-
tient had undergone previous treatment for his melanoma, in-
cluding a wide local excision, lymph node dissection, chemo-
therapy with DTIC, cw-platinum, and tamoxifen, B C G and 
IL-2 immunotherapy, interferon-"/ (IFN--Y) immunotherapy, 
and radiation. The patient was refractory to these treatments, 
and had recurrent melanoma on the chest wall and back, axil-
lary lymph nodes, and lungs, confirmed by biopsy, thoracente-
sis, and post mortem examination. This patient was H L A - B 7 ~ , 
HLA-l"*-, and haplotype B5, 57, and W 4 ^ . 
The patient received two courses of H L A - B 7 gene treatment 
by direct intratomor injection into cutaneous melanoma nodules 
on the left lower chest (treatment #1) and left upfwr chest 
(treatment #2). H e responded to these treatments, showing 
complete regression of both treated nodules, as well as a 3-cm 
pulmonary nodule (Nabel et al., 1993a). N o evidence of toxic-
ity was observed in this patient or any others stodied in this trial 
(Table 1; see also Nabel et al., 1993a). However, the patient 
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Hematology, chemistry, and immunology toxicity proflles of patients treated by gene transfer of H L A - B 7 . Pt. 3 refers to the subject described in 
the present report. Five patients with stage IV melanoma refractory to all available therapies were enrolled based on guidelines of the clinical 
protocol (Nabel et al., 1992a, 1993a). These patients were H L A - B 7 negative, greater than 18 years of age, H I V negative, and infertile. Blank 
spaces indicate that values were not determined. 
had at least t w o unresponsive pulmonary lesions, including a 
large right lower lobe m a s s identified b y analysis of anterior-
posterior and lateral views o n chest film and computerized 
tomography of the chest. This m a s s w a s associated with the 
right posterior basal artery. Based o n his previous reponse to 
this treatment, w e considered the possibility of delivering the 
recombinant gene to the pulmonary nodule b y catheterization. 
Permission to perform this procedure w a s sought and obtained 
from the Recombinant D N A Advisory Committee and the Food 
and Drug Administration. 
Informed consent was obtained from the patient, and the 
patient underwent two percutaneous transcatheter treatments to 
the right posterior basal artery, 2 weeks apart (Fig. 1). During 
each treatment, 0.6 ml of DNA-liposome solution was admin-
istered followed by an additional total of 4 ml of sterile saline 
to distribute it to the local microcirculation. Both treatments 
were well tolerated, without acute complications. There were 
no E C G abnormalities or arrhythmias during both treat-
ments. Analysis of hemodynamic parameters revealed no 
Table 2. Systemic and Pulmonary Hemodynamic 
Measltrements During Pulmonary Artery 
Gene Transfer 
Treatment 1 Treatment 2 
Pre Post Pre Post 
Systemic blood pressure 
(mmHg) 
Puhnonary artery pressure 
(mmHg) 
Pulmonary capillary wedge 
pressure (mean) (mmHg) 
121/71 128/76 111/74 116/78 
28/8 27/8 22/4 23/5 
15 16 10 11 
Hemodynamic measurements of systemic and pulmonary artery pres-
sures 5 min prior to and 20 min after catheter delivery of D N A -
liposomes into the right posterior basal segment artery. 
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changes in pulmonary artery, pulmonary capillary wedge, or 
systemic arterial pressures measured 5 min before and 20 min 
after transcatheter injection (Table 2). The pulmonary artery 
pressure remained at 28/8 m m H g (treatment #1), and 22/4 
m m H g (h-eatment #2), and the pulmonary capillary wedge 
pressure was 15 and 10 m m H g during treatments 1 and 2, 
respectively. 
Analysis of hematological and biochemical parameters re-
vealed no systemic abnormalities in this patient, including mea-
sures of liver, renal, pancreatic, and cardiac function prior to or 
after the two transcatheter gene deliveries. Serum blood sam-
ples obtained during the pulmonary artery infusion were ana-
lyzed by the polymerase chain reaction (PCR) for the presence 
of plasmid D N A . In this patient, plasmid D N A was not detected 
in systemic blood during either treatment (sensitivity < 2 pg/ 
ml). Myocardial abnormalities were not detected by analysis of 
creatine kinase in the serum of this patient prior to, during, or 
after the treatments. Likewise, no anti-DNA antibodies were 
detected in the patient (Table 3). T w o weeks following the 
second treatment, a lung biopsy was considered but was not 
performed due to poor respiratory status of the patient. A right 
pleural thoracentesis was performed to relieve a chronic pleural 
effusion from this lung. Cytologies revealed that the lesion 
represented a second independent malignancy, an adenocarci-
noma, in the right lung distinct from the previously treated 
melanoma. The patient died 9 months later, and a post mortem 
examination confirmed the diagnosis of a second malignancy, 
an adenocarcinoma, in the right lung (Fig. 2). 
D I S C U S S I O N 
In this case report, a human HLA-B7 gene was delivered by 
catheter injection into the pulmonjuy artery associated with 
metastatic lung nodules of an HLA-B7-negative patient. The 
treatments were well tolerated. N o apparent toxicities were 
observed. Pulmonary and systemic arterial pressures were nor-
mal, biochemical parameters were normal, and no anti-DNA 
antibodies were detected. 
Local drug delivery, including site-specific gene transfer, 
offers several advantages compared with systemic drug ther-
apy. Local administration of a drug or recombinant D N A can 
potentially result in high local and low systemic concentrations 
of an agent, which may minimize systemic toxicities. Several 
approaches to local delivery are feasible, including implantable 
subcutaneous pumps, encapsulation of drug within a polymer 
gel (Langer and Vacanti, 1993), and indwelling vascular cathe-
ters (Kennedy er a/., 1985; Ensminger, 1993). Prototype cathe-
ters have been developed and tested in vivo for local drug 
delivery into vascular thromboses and for vascular gene trans-
fer, including double balloon catheters (Nabel et al., 1990), 
porous balloons (Wolinsky and Thung, 1990), catheters coated 
with polymer gels (Riessen et al., 1993), and autoperfusion 
catheters. These stodies suggest that drugs, such as throm-
bolytic agents, can be delivered into focal vascular thromboses, 
achieving high local concentrations of drug and with less toxic-
ity than might be incurred if equivalent doses were delivered 
systemically. These devices will require future modifications to 
optimize delivery, minimize local tissue damage, and permit 
vessel Jjerfusion. Previous methods of local drug delivery are 
Table 3. Hematology, Chemistry, and Immunology 




White blood count 
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Alkaline phosphatase (IU/1) 
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Hematology, chemistry, and immunology parameters in the patient 1 
day before and 1 day after catheter delivery of DNA-liposomes into the 
right posterior basal segment artery. N.D. indicates values not deter-
mined. Although CH50 was elevated, this and other immunologic val-
ues were unchanged from baseline values (see Table 1). 
limited, however, by the rapid clearance of drug following 
restoration of blood flow. Introduction of a recombinant gene 
into vascular tissue by catheter might provide for a sustained 
and localized effect of a therapeutic protein. 
Transcatheter injection of recombinant genes into selective 
sites in the vasculatore is one approach to the genetic treatment 
of cancer and/or vascular diseases that provides targeted expres-
sion in vivo. Endolumenal vascular gene transfer has been 
achieved in several animal models, including pigs (Nabel et al., 
1990, 1993b), dogs (Lim et al., 1991; Chapman et al., 1992), 
rabbits (LeClerc et al., 1992; B a n et al., 1994), and rats (Mor-
ishita et al., 1993). Direct gene transfer to the vasculature has 
been well tolerated in animal models using cationic liposomes 
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FIG. 2. Histology of representative sections from melanoma lesions in the patient's left or right axilla (A) and adenocarcinoma 
from the right lower lung (B). Magnification, 400x; hematoxylin and eosin stain. 
(Nabel et al., 1992b; San et al., 1993) with minimal toxicities. 
Recent stodies from our laboratory suggest that catheter deliv-
ery of D N A to porcine pulmonary arteries using liposomes and 
adenoviral vectors results in gene expression in pulmonary ar-
teries, capillaries and veins as well as distal alveoli (Muller 
etal., 1994). While these stodies have suggested that endovas-
cular gene transfer is achievable by catheter delivery, its feasi-
bility in humans was not previously tested. The findings in this 
case report suggest that transcatheter injection of DNA-lipo-
somes into the pulmonary vasculatore is a safe and nontoxic 
approach to the treatment of pulmonary malignancies and/or 
vascular diseases. These findings suggest that further develop-
ment of catheters designed to treat focal diseases in humans is 
wananted and could be applied to the treatment of cancer and 
vascular diseases. 
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